Skip to main content
SpringerLink
Log in

PI3K as a Target for Therapy in Haematological Malignancies

  • Chapter
  • First Online:
Phosphoinositide 3-kinase in Health and Disease

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 347))

Abstract

Although classical mutations in genes such as PIK3CA and PTEN occur at a relatively low frequency in haematological malignancies, activation of PI3K signalling is often detected in these tumours. In some conditions, for example acute myeloid leukaemia (AML), this is due to activating mutations of upstream regulators such as the FLT3 tyrosine kinase or RAS. Primary tumour cells taken from patients with AML, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and multiple myeloma show varying levels of sensitivity to PI3K and mTOR inhibitors. The challenge now is to conduct high quality trials with novel agents that target these pathways to establish the level of clinical response and to identify those subsets of patients that are more likely to respond.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abubaker J, Bavi PP et al (2007) PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 21(11):2368–2370

    Article  PubMed  CAS  Google Scholar 

  • Agazie YM, Movilla N et al (2003) The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene 22(44):6909–6918

    Article  PubMed  CAS  Google Scholar 

  • Aggerholm A, Gronbaek K et al (2000) Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol 65(2):109–113

    Article  PubMed  CAS  Google Scholar 

  • Agliano A, Martin-Padura I et al (2008) Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 123(9):2222–2227

    Article  PubMed  CAS  Google Scholar 

  • Ailles LE, Gerhard B et al (1999) Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 94(5):1761–1772

    PubMed  CAS  Google Scholar 

  • Ali K, Bilancio A et al (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431(7011):1007–1011

    Article  PubMed  CAS  Google Scholar 

  • Ali K, Camps M et al (2008) Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 180(4):2538–2544

    PubMed  CAS  Google Scholar 

  • Allavena P, Sica A et al (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66(1):1–9

    Article  PubMed  Google Scholar 

  • Ansell SM, Inwards DJ et al (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 113(3):508–514

    Article  PubMed  CAS  Google Scholar 

  • Aster JC, Pear WS et al (2008) Notch signaling in leukemia. Annu Rev Pathol 3:587–613

    Article  PubMed  CAS  Google Scholar 

  • Bai RY, Ouyang T et al (2000) Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96(13):4319–4327

    PubMed  CAS  Google Scholar 

  • Banerjee L, Mansour M et al (2009) Combined blockade of PI3-kinase and mTOR synergizes with gamma-secretase inhibitors to induce a high level of cell death in T-cell acute lymphoblastic leukaemia cells with activated Notch signalling. Br J Haematol 145(Suppl 1):9–10

    Google Scholar 

  • Baohua Y, Xiaoyan Z et al (2008) Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol 17(3):159–165

    Article  PubMed  CAS  Google Scholar 

  • Bardet V, Tamburini J et al (2006) Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica 91(6):757–764

    PubMed  CAS  Google Scholar 

  • Baumann P, Mandl-Weber S et al (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 315(3):485–497

    Article  PubMed  CAS  Google Scholar 

  • Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23(26):6333–6338

    Article  PubMed  CAS  Google Scholar 

  • Bichi R, Shinton SA et al (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 99(10):6955–6960

    Article  PubMed  CAS  Google Scholar 

  • Billottet C, Grandage VL et al (2006) A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25(50):6648–6659

    Article  PubMed  CAS  Google Scholar 

  • Billottet C, Banerjee L et al (2009) Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res 69(3):1027–1036

    Article  PubMed  CAS  Google Scholar 

  • Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737

    Article  PubMed  CAS  Google Scholar 

  • Bowen DT, Frew ME et al (2005) RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 106(6):2113–2119

    Article  PubMed  CAS  Google Scholar 

  • Brachmann S, Fritsch C et al (2009) PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 21(2):194–198

    Article  PubMed  CAS  Google Scholar 

  • Brandts CH, Sargin B et al (2005) Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 65(21):9643–9650

    Article  PubMed  CAS  Google Scholar 

  • Burchert A, Wang Y et al (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19(10):1774–1782

    Article  PubMed  CAS  Google Scholar 

  • Caligaris-Cappio F, Ghia P (2008) Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 26(27):4497–4503

    Article  PubMed  CAS  Google Scholar 

  • Chang H, Qi XY et al (2006) Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 30(3):262–265

    Article  PubMed  CAS  Google Scholar 

  • Chiorazzi N, Ferrarini M (2006) Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Hematology Am Soc Hematol Educ Program 273–8:512

    Google Scholar 

  • Collins SJ (2008) Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr Opin Hematol 15(4):346–351

    Article  PubMed  CAS  Google Scholar 

  • Collins RJ, Verschuer LA et al (1989) Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 71(3):343–350

    Article  PubMed  CAS  Google Scholar 

  • Condliffe AM, Davidson K et al (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106(4):1432–1440

    Article  PubMed  CAS  Google Scholar 

  • Cornillet-Lefebvre P, Cuccuini W et al (2006) Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations. Leukemia 20(2):374–376

    Article  PubMed  CAS  Google Scholar 

  • Cutillas PR, Khwaja A et al (2006) Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc Natl Acad Sci USA 103(24):8959–8964

    Article  PubMed  CAS  Google Scholar 

  • Dal Col J, Zancai P et al (2008) Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111(10):5142–5151

    Article  PubMed  CAS  Google Scholar 

  • Daley GQ, Van Etten RA et al (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247(4944):824–830

    Article  PubMed  CAS  Google Scholar 

  • De Keersmaecker K, Lahortiga I et al (2008) In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 93(4):533–542

    Article  PubMed  CAS  Google Scholar 

  • Decker T, Sandherr M et al (2009) A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 88(3):221–227

    Article  PubMed  CAS  Google Scholar 

  • Delwel R, Dorssers L et al (1987) Human recombinant multilineage colony stimulating factor (interleukin-3): stimulator of acute myelocytic leukemia progenitor cells in vitro. Blood 70(1):333–336

    PubMed  CAS  Google Scholar 

  • Demarest RM, Ratti F et al (2008) It’s T-ALL about Notch. Oncogene 27(38):5082–5091

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112(13):4808–4817

    Article  PubMed  CAS  Google Scholar 

  • Farag SS, Zhang S et al (2009) Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 33(11):1475–1480

    Article  PubMed  CAS  Google Scholar 

  • Feuring-Buske M, Gerhard B et al (2003) Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17(4):760–763

    Article  PubMed  CAS  Google Scholar 

  • Fielding AK, Rowe JM et al (2009) Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 113(19):4489–4496

    Article  PubMed  CAS  Google Scholar 

  • Flex E, Petrangeli V et al (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 205(4):751–758

    Article  PubMed  CAS  Google Scholar 

  • Fonseca R, Barlogie B et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64(4):1546–1558

    Article  PubMed  CAS  Google Scholar 

  • Fruman DA, Bismuth G (2009) Fine tuning the immune response with PI3K. Immunol Rev 228(1):253–272

    Article  PubMed  CAS  Google Scholar 

  • Gale RE, Green C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):2776–2784

    Article  PubMed  CAS  Google Scholar 

  • Gallay N, Dos Santos C et al (2009) The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23(6):1029–1038

    Article  PubMed  CAS  Google Scholar 

  • Gao T, Furnari F et al (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18(1):13–24

    Article  PubMed  CAS  Google Scholar 

  • Garrido SM, Appelbaum FR et al (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29(4):448–457

    Article  PubMed  CAS  Google Scholar 

  • Goldstone AH, Richards SM et al (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111(4):1827–1833

    Article  PubMed  CAS  Google Scholar 

  • Grandage VL, Gale RE et al (2005) PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19(4):586–594

    PubMed  CAS  Google Scholar 

  • Graux C, Cools J et al (2004) Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 36(10):1084–1089

    Article  PubMed  CAS  Google Scholar 

  • Grigorieva I, Thomas X et al (1998) The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 26(7):597–603

    PubMed  CAS  Google Scholar 

  • Grulich AE, van Leeuwen MT et al (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581):59–67

    Article  PubMed  Google Scholar 

  • Gutierrez A, Sanda T et al (2009) High frequency of PTEN, PI3K and AKT abnormalities in T cell acute lymphoblastic leukemia. Blood 114(3):647–650

    Article  PubMed  CAS  Google Scholar 

  • Haneline LS, White H et al (2006) Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo. Blood 107(4):1375–1382

    Article  PubMed  CAS  Google Scholar 

  • Hashemolhosseini S, Nagamine Y et al (1998) Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273(23):14424–14429

    Article  PubMed  CAS  Google Scholar 

  • Herling M, Patel KA et al (2006) TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20(2):280–285

    Article  PubMed  CAS  Google Scholar 

  • Herling M, Patel KA et al (2008) High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111(1):328–337

    Article  PubMed  CAS  Google Scholar 

  • Hu L, Shi Y et al (2003) Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101(8):3126–3135

    Article  PubMed  CAS  Google Scholar 

  • Huettner CS, Zhang P et al (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24(1):57–60

    Article  PubMed  CAS  Google Scholar 

  • Hummerdal P, Andersson P et al (2006) Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia. Eur J Haematol 77(1):86–87

    Article  PubMed  CAS  Google Scholar 

  • Ihle NT, Powis G (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 8(1):1–9

    Article  PubMed  CAS  Google Scholar 

  • Jorgensen HG, Holyoake TL (2007) Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 35(Pt 5):1347–1351

    PubMed  CAS  Google Scholar 

  • Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239–252

    Article  PubMed  CAS  Google Scholar 

  • Kang S, Denley A et al (2006) Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 103(5):1289–1294

    Article  PubMed  CAS  Google Scholar 

  • Kharas MG, Fruman DA (2005) ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65(6):2047–2053

    Article  PubMed  CAS  Google Scholar 

  • Kharas MG, Janes MR et al (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 118(9):3038–3050

    Article  PubMed  CAS  Google Scholar 

  • Kim N, Saudemont A et al (2007) The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 110(9):3202–3208

    Article  PubMed  CAS  Google Scholar 

  • Kim MS, Jeong EG et al (2008) Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98(9):1533–1535

    Article  PubMed  CAS  Google Scholar 

  • Knight ZA, Gonzalez B et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125(4):733–747

    Article  PubMed  CAS  Google Scholar 

  • Kojima K, Shimanuki M et al (2008) The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22(9):1728–1736

    Article  PubMed  CAS  Google Scholar 

  • Lagneaux L, Delforge A et al (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91(7):2387–2396

    PubMed  CAS  Google Scholar 

  • Laine J, Kunstle G et al (2000) The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 6(2):395–407

    Article  PubMed  CAS  Google Scholar 

  • Lanham S, Hamblin T et al (2003) Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101(3):1087–1093

    Article  PubMed  CAS  Google Scholar 

  • Larson Gedman A, Chen Q et al (2009) The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 23(8):1417–1425

    Article  PubMed  CAS  Google Scholar 

  • Leverrier Y, Okkenhaug K et al (2003) Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem 278(40):38437–38442

    Article  PubMed  CAS  Google Scholar 

  • Liu TC, Lin PM et al (2000) Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 63(4):170–175

    Article  PubMed  CAS  Google Scholar 

  • Longo PG, Laurenti L et al (2008) The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111(2):846–855

    Article  PubMed  CAS  Google Scholar 

  • Mahmoud IS, Sughayer MA et al (2008) The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer 99(3):488–490

    Article  PubMed  CAS  Google Scholar 

  • Maira SM, Stauffer F et al (2009) PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans 37(Pt 1):265–272

    Article  PubMed  CAS  Google Scholar 

  • Martinez N, Camacho FI et al (2003) The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 63(23):8226–8232

    PubMed  CAS  Google Scholar 

  • Mazurier F, Doedens M et al (2003) Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med 9(7):959–963

    Article  PubMed  CAS  Google Scholar 

  • Mead AJ, Linch DC et al (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110(4):1262–1270

    Article  PubMed  CAS  Google Scholar 

  • Min YH, Cheong JW et al (2004) Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 64(15):5225–5231

    Article  PubMed  CAS  Google Scholar 

  • Miyamoto K, Araki KY et al (2007) Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1(1):101–112

    Article  PubMed  CAS  Google Scholar 

  • Mohi MG, Boulton C et al (2004) Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101(9):3130–3135

    Article  PubMed  CAS  Google Scholar 

  • Narducci MG, Stoppacciaro A et al (1997) TCL1 is overexpressed in patients affected by adult T-cell leukemias. Cancer Res 57(24):5452–5456

    PubMed  CAS  Google Scholar 

  • Niedermeier M, Hennessy BT et al (2009) Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113(22):5549–5557

    Article  PubMed  CAS  Google Scholar 

  • Ouillette P, Erba H et al (2008) Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 68(4):1012–1021

    Article  PubMed  CAS  Google Scholar 

  • Palomero T, Sulis ML et al (2007) Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13(10):1203–1210

    Article  PubMed  CAS  Google Scholar 

  • Papakonstanti EA, Ridley AJ et al (2007) The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J 26(13):3050–3061

    Article  PubMed  CAS  Google Scholar 

  • Papakonstanti EA, Zwaenepoel O et al (2008) Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci 121(pt 24):4124–4133

    Article  PubMed  CAS  Google Scholar 

  • Park S, Chapuis N et al (2008) PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22(9):1698–1706

    Article  PubMed  CAS  Google Scholar 

  • Patton DT, Garden OA et al (2006) Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 177(10):6598–6602

    PubMed  CAS  Google Scholar 

  • Pearce DJ, Taussig D et al (2006) AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107(3):1166–1173

    Article  PubMed  CAS  Google Scholar 

  • Pekarsky Y, Koval A et al (2000) Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 97(7):3028–3033

    Article  PubMed  CAS  Google Scholar 

  • Pekarsky Y, Santanam U et al (2006) Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 66(24):11590–11593

    Article  PubMed  CAS  Google Scholar 

  • Pene F, Claessens YE et al (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21(43):6587–6597

    Article  PubMed  CAS  Google Scholar 

  • Peponi E, Drakos E et al (2006) Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169(6):2171–2180

    Article  PubMed  CAS  Google Scholar 

  • Perentesis JP, Bhatia S et al (2004) RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia 18(4):685–692

    Article  PubMed  CAS  Google Scholar 

  • Podar K, Chauhan D et al (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23(1):10–24

    Article  PubMed  CAS  Google Scholar 

  • Pui CH, Robison LL et al (2008) Acute lymphoblastic leukaemia. Lancet 371(9617):1030–1043

    Article  PubMed  CAS  Google Scholar 

  • Puri KD, Doggett TA et al (2004) Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 103(9):3448–3456

    Article  PubMed  CAS  Google Scholar 

  • Quentmeier H, Reinhardt J et al (2003) FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17(1):120–124

    Article  PubMed  CAS  Google Scholar 

  • Quentmeier H, Martelli MP et al (2005) Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 19(10):1760–1767

    Article  PubMed  CAS  Google Scholar 

  • Raje N, Kumar S et al (2004) Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104(13):4188–4193

    Article  PubMed  CAS  Google Scholar 

  • Randis TM, Puri KD et al (2008) Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol 38(5):1215–1224

    Article  PubMed  CAS  Google Scholar 

  • Renneville A, Roumier C et al (2008) Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 22(5):915–931

    Article  PubMed  CAS  Google Scholar 

  • Rizzieri DA, Feldman E et al (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14(9):2756–2762

    Article  PubMed  CAS  Google Scholar 

  • Rousselot P, Huguet F et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109(1):58–60

    Article  PubMed  CAS  Google Scholar 

  • Rudelius M, Pittaluga S et al (2006) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108(5):1668–1676

    Article  PubMed  CAS  Google Scholar 

  • San-Miguel J, Harousseau JL et al (2008) Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 26(16):2761–2766

    Article  PubMed  CAS  Google Scholar 

  • Sattler M, Verma S et al (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275(32):24273–24278

    Article  PubMed  CAS  Google Scholar 

  • Saudemont A, Okkenhaug K et al (2007) p110delta is required for innate immunity to transplantable lymphomas. Biochem Soc Trans 35(pt 2):183–185

    PubMed  CAS  Google Scholar 

  • Saudemont A, Garcon F et al (2009) p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proc Natl Acad Sci USA 106(14):5795–5800

    Article  PubMed  CAS  Google Scholar 

  • Savitskiy VP, Shman TV et al (2003) Comparative measurement of spontaneous apoptosis in pediatric acute leukemia by different techniques. Cytometry B Clin Cytom 56(1):16–22

    Article  PubMed  Google Scholar 

  • Schiffer CA (2008) Molecular characterization of AML: a significant advance or just another prognostic factor? Best Pract Res Clin Haematol 21(4):621–628

    Article  PubMed  CAS  Google Scholar 

  • Shi Y, Gera J et al (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62(17):5027–5034

    PubMed  CAS  Google Scholar 

  • Shi Y, Yan H et al (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4(10):1533–1540

    Article  PubMed  CAS  Google Scholar 

  • Shimada Y, Maeda M et al (2003) Cell culture in esophageal squamous cell carcinoma and the association with molecular markers. Clin Cancer Res 9(1):243–249

    PubMed  CAS  Google Scholar 

  • Sillaber C, Mayerhofer M et al (2008) Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 38(1):43–52

    Article  PubMed  CAS  Google Scholar 

  • Silva A, Yunes JA et al (2008) PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118(11):3762–3774

    Article  PubMed  CAS  Google Scholar 

  • Skorski T, Bellacosa A et al (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16(20):6151–6161

    Article  PubMed  CAS  Google Scholar 

  • Slupianek A, Nieborowska-Skorska M et al (2001) Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61(5):2194–2199

    PubMed  CAS  Google Scholar 

  • Stockmann C, Doedens A et al (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456(7223):814–818

    Article  PubMed  CAS  Google Scholar 

  • Sujobert P, Bardet V et al (2005) Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106(3):1063–1066

    Article  PubMed  CAS  Google Scholar 

  • Tamburini J, Elie C et al (2007) Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110(3):1025–1028

    Article  PubMed  CAS  Google Scholar 

  • Taussig DC, Miraki-Moud F et al (2008) Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112(3):568–575

    Article  PubMed  CAS  Google Scholar 

  • Tazzari PL, Tabellini G et al (2007) The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 21(5):886–896

    PubMed  CAS  Google Scholar 

  • Teachey DT, Obzut DA et al (2006) The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107(3):1149–1155

    Article  PubMed  CAS  Google Scholar 

  • Teachey DT, Sheen C et al (2008) mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112(5):2020–2023

    Article  PubMed  CAS  Google Scholar 

  • Teachey DT, Grupp SA et al (2009) Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 145(5):569–580

    Article  PubMed  CAS  Google Scholar 

  • Thompson JE, Conlon JP et al (2007) Enhanced growth of myelodysplastic colonies in hypoxic conditions. Exp Hematol 35(1):21–31

    Article  PubMed  CAS  Google Scholar 

  • Ticchioni M, Essafi M et al (2007) Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene 26(50):7081–7091

    Article  PubMed  CAS  Google Scholar 

  • Touw I, Pouwels K et al (1990) Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 75(11):2097–2101

    PubMed  CAS  Google Scholar 

  • Uddin S, Hussain AR et al (2006) Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108(13):4178–4186

    Article  PubMed  CAS  Google Scholar 

  • Virgilio L, Narducci MG et al (1994) Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 91(26):12530–12534

    Article  PubMed  CAS  Google Scholar 

  • Wee S, Jagani Z et al (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69(10):4286–4293

    Article  PubMed  CAS  Google Scholar 

  • Weng AP, Ferrando AA et al (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306(5694):269–271

    Article  PubMed  CAS  Google Scholar 

  • Xu Q, Simpson SE et al (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102(3):972–980

    Article  PubMed  CAS  Google Scholar 

  • Yazbeck VY, Buglio D et al (2008) Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36(4):443–450

    Article  PubMed  CAS  Google Scholar 

  • Yee KW, Zeng Z et al (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12(17):5165–5173

    Article  PubMed  CAS  Google Scholar 

  • Yilmaz OH, Valdez R et al (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441(7092):475–482

    Article  PubMed  CAS  Google Scholar 

  • Young DC, Griffin JD (1986) Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 68(5):1178–1181

    PubMed  CAS  Google Scholar 

  • Zebedin E, Simma O et al (2008) Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood 112(12):4655–4664

    Article  PubMed  CAS  Google Scholar 

  • Zenz T, Dohner K et al (2008) Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations. Br J Haematol 141(5):742–743

    Article  PubMed  CAS  Google Scholar 

  • Zhang J, Choi Y et al (2003) Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene 22(40):6289–6295

    Article  PubMed  CAS  Google Scholar 

  • Zhang J, Grindley JC et al (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441(7092):518–522

    Article  PubMed  CAS  Google Scholar 

  • Zollinger A, Stuhmer T et al (2008) Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 112(8):3403–3411

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK

    Asim Khwaja

Authors
  1. Asim Khwaja
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asim Khwaja .

Editor information

Editors and Affiliations

  1. Intellikine, North Torreye Pines Road 10931, La Jolla, 92037, California, USA

    Christian Rommel

  2. , Institute of Cancer and the London Schoo, Queen Mary, University of London, Charterhouse Square, London, EC1M 6BQ, United Kingdom

    Bart Vanhaesebroeck

  3. , Dept. Molecular & Exp. Medicine, Scripps Research Institute, N. Torrey Pines Road 10550, La Jolla, 92037, California, USA

    Peter K. Vogt

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Khwaja, A. (2010). PI3K as a Target for Therapy in Haematological Malignancies. In: Rommel, C., Vanhaesebroeck, B., Vogt, P. (eds) Phosphoinositide 3-kinase in Health and Disease. Current Topics in Microbiology and Immunology, vol 347. Springer, Berlin, Heidelberg. https://doi.org/10.1007/82_2010_71

Download citation

Publish with us

Policies and ethics

Search

Navigation